The enhanced spatial resolution of ultra-high field 7T magnetic resonance imaging (MRI) has demonstrated that >80% of white matter lesions in MS patients have a central vein (21) and natalizumab, an anti-α4 integrin monoclonal antibody that blocks cell-cell interactions between VLA-4 (α4β1 integrin, CD49d/CD29 heterodimer, also known as very late antigen-4) expressed on activated immune cells and vascular cell adhesion molecule (VCAM-1) expressed on the vascular endothelium is an approved drug for treating MS. This evidence concerns the gene ITGB1 and myeloid sarcoma.